Projects per year
Fingerprint The fingerprint is based on mining the text of the scientific documents related to the associated persons. Based on that an index of weighted terms is created, which defines the key subjects of research unit
Prostatic Neoplasms
Medicine & Life Sciences
Prostatectomy
Medicine & Life Sciences
Urinary Bladder Neoplasms
Medicine & Life Sciences
Renal Cell Carcinoma
Medicine & Life Sciences
Neoplasms
Medicine & Life Sciences
Castration
Medicine & Life Sciences
Androgens
Medicine & Life Sciences
Prostate-Specific Antigen
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Profiles
Anna Ferrari
- Cancer Institute of New Jersey (CINJ), Urologic Oncology - PROF-CLIN
- Clinical Investigations and Precision Therapeutics Program, CINJ - FULL MEMBER
Person
Isaac Kim
- Cancer Institute of New Jersey (CINJ), Urologic Oncology - PROF-TE-DIV CHIEF
- Clinical Investigations and Precision Therapeutics Program, CINJ - FULL MEMBER
Person
Eric Singer
- Cancer Institute of New Jersey (CINJ), Urologic Oncology - ASST PROF-CLIN
- Clinical Investigations and Precision Therapeutics Program, CINJ - ASSOCIATE MEMBER
Person
Projects 2010 2020
Neuroendocrine Differentiation And Enzalutamide Resistance In Prostate Cancer
Congressionally Directed Medical Research Programs (CDMRP)
9/1/17 → 8/31/20
Project: Research project
Parathyroid Hormone-Related Protein
Prostatic Neoplasms
Castration
Cell Line
Catenins
Therapeutic Role Of Bmi-1 Inhibitors In Eliminating Prostate Tumor Stem Cells
Congressionally Directed Medical Research Programs (CDMRP)
9/30/12 → 9/29/15
Project: Research project
Neoplastic Stem Cells
Prostate
Heterografts
Therapeutics
Neoplasms
The Dean And Betty Gallo Prostate Cancer Center: Development Of Shared Resources For Prostate Cancer Research
Congressionally Directed Medical Research Programs (CDMRP)
8/1/10 → 1/31/15
Project: Research project
Prostatic Neoplasms
Research
Education
Patient Care
Research Personnel
Research Output 1996 2019
4
Citations
(Scopus)
A phase II trial of the aurora kinase a inhibitor alisertib for patients with castration-resistant and neuroendocrine prostate cancer: Efficacy and biomarkers
Beltran, H., Oromendia, C., Danila, D. C., Montgomery, B., Hoimes, C., Szmulewitz, R. Z., Vaishampayan, U., Armstrong, A. J., Stein, M., Pinski, J., Mosquera, J. M., Sailer, V., Bareja, R., Romanel, A., Gumpeni, N., Sboner, A., Dardenne, E., Puca, L., Prandi, D., Rubin, M. A. & 6 others, Jan 1 2019, In : Clinical Cancer Research. 25, 1, p. 43-51 9 p.Research output: Contribution to journal › Article
Aurora Kinases
Castration
Tumor Biomarkers
Prostatic Neoplasms
Organoids
AUTHOR REPLY
Farber, N. J., Neylan, C. J., Singer, E. & Elsamra, S. E., Jun 1 2019, In : Urology. 128, p. 29-30 2 p.Research output: Contribution to journal › Comment/debate
Autophagy inhibition to augment mTOR inhibition: A phase I/II trial of everolimus and hydroxychloroquine in patients with previously treated renal cell carcinoma
Haas, N. B., Appleman, L. J., Stein, M., Redlinger, M., Wilks, M., Xu, X., Onorati, A., Kalavacharla, A., Kim, T., Zhen, C. J., Kadri, S., Segal, J. P., Gimotty, P. A., Davis, L. E. & Amaravadi, R. K., Apr 1 2019, In : Clinical Cancer Research. 25, 7, p. 2080-2087 8 p.Research output: Contribution to journal › Article
Hydroxychloroquine
Autophagy
Renal Cell Carcinoma
Disease-Free Survival
Everolimus